Workflow
Bluejay Diagnostics(BJDX)
icon
Search documents
Bluejay Diagnostics(BJDX) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
We are also a "smaller reporting company," meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock hel ...
Bluejay Diagnostics(BJDX) - 2023 Q2 - Quarterly Report
2023-08-13 16:00
Financial Performance - The company reported a net loss of $2.81 million for the three months ended June 30, 2023, compared to a net loss of $1.94 million for the same period in 2022, reflecting an increase in operating expenses[32]. - Revenue for the six months ended June 30, 2023, was $249,040 million, unchanged from the same period in 2022[40]. - Net loss for the six months ended June 30, 2023, was $5,252,148 million, compared to a net loss of $3,950,805 million in the same period of 2022, indicating a 33% increase in losses[40]. - Other income for the six months ended June 30, 2023, was $230,112 million, compared to $103,181 million in 2022, showing a significant increase of 123%[40]. Operating Expenses - Total operating expenses for the three months ended June 30, 2023, were $2.90 million, up from $2.03 million in the same period of 2022, with research and development costs increasing to $1.68 million from $0.76 million[32]. - Total operating expenses for the six months ended June 30, 2023, increased to $5,583,260 million from $4,102,897 million in 2022, representing a 36% increase[40]. - Research and development expenses for the six months ended June 30, 2023, were $3,030,805 million, up from $1,451,040 million in 2022, reflecting a 108% increase[40]. - General and administrative expenses decreased to $2,250,080 million for the six months ended June 30, 2023, from $2,516,815 million in 2022, a reduction of 11%[40]. Cash and Liabilities - As of June 30, 2023, the company had cash and cash equivalents of $5.1 million and estimated that these resources would be sufficient to fund operations into the fourth quarter of 2023[18]. - The company incurred approximately $1.8 million in current liabilities and commitments of about $1.9 million as of June 30, 2023[18]. - Total lease liabilities decreased to $442,928 million as of June 30, 2023, from $513,251 million as of December 31, 2022, a decline of 14%[54]. - The company has a minimum royalty payment obligation of $100,000 per year to Toray Industries following the first sale of Cartridges, which has not yet occurred as of June 30, 2023[56]. Stock and Shares - The company executed a reverse stock split at a ratio of 1-for-20 on July 24, 2023, reducing the number of authorized outstanding shares from 100 million to 7.5 million[17]. - The company’s weighted average common shares outstanding for the three months ended June 30, 2023, were 1,023,052, reflecting a 1-for-20 reverse stock split[32]. Clinical Development - The company plans to conduct a clinical study to support an FDA regulatory submission for the Symphony IL-6 test, with a timeline for submission in the first half of 2024[36]. - The company is developing the Symphony device for measuring IL-6, which is intended for monitoring disease progression in critical care settings[35]. - The company is reliant on Toray and Sanyoseiko for cartridges necessary for clinical trials, with potential supply interruptions posing risks to trial timelines[37]. Reporting Classification - The company is classified as a smaller reporting company, with a market value of stock held by non-affiliates below $700 million and annual revenue under $100 million[61].
Bluejay Diagnostics(BJDX) - 2023 Q1 - Quarterly Report
2023-05-10 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR Commission file number: 001-41031 47-3552922 (I.R.S. Employer Identification No.) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...
Bluejay Diagnostics(BJDX) - 2022 Q4 - Annual Report
2023-03-19 16:00
For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in Its Charter) TABLE OF CONTENTS | --- | --- | --- | |------------|----------------------------------------------------------------------------------------------|-------| | | | Page | | CAUTIONARY | NOTE REGARDING FORWARD-LOOKING STATEMENTS | ii | | SUMMARY | OF RISK FACTOR ...
Bluejay Diagnostics(BJDX) - 2022 Q3 - Quarterly Report
2022-11-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to__________ Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in Its Charter) | --- | |------ ...
Bluejay Diagnostics (BJDX) Investor Presentation - Slideshow
2022-09-14 13:44
September 2022 00 DIAG 0 O OG O ● Disclaimer Forward-looking Statements CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future eve ...
Bluejay Diagnostics(BJDX) - 2022 Q2 - Quarterly Report
2022-08-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 47-3552922 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒ Smaller Reporting Company ☒ Emerging Growth Company ☒ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock BJDX The Nasdaq Capital Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 ...
Bluejay Diagnostics(BJDX) - 2022 Q1 - Quarterly Report
2022-05-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | |------ ...
Bluejay Diagnostics(BJDX) - 2021 Q4 - Annual Report
2022-03-09 16:00
| --- | --- | --- | --- | |---------------------------------------------------------------------------------------|-------|-------|-----------------------------------------------------| | | | | | | Delaware (State or Other Jurisdiction of Incorporation or Organization) | | | 47-3552922 (I.R.S. Employer Identification No.) | | 360 Massachusetts Avenue, Suite 203, Acton, MA | | | 01720 | | (Address of Principal Executive Offices) | | | (Zip Code) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, ...
Bluejay Diagnostics(BJDX) - 2021 Q3 - Quarterly Report
2021-12-15 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number: 001-41031 Bluejay Diagnostics, Inc. (Exact Name of Registrant as Specified in Its Charter) | --- | --- | |-- ...